Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm.
Abstract
[BACKGROUND] Hemifacial spasm (HFS) is a debilitating disease characterized by involuntary tonic and clonic contractions of muscles innervated by the facial nerve. Botulinum toxin A (BTX-A) is the first-line option and the most effective medical treatment for HFS. The objective of this study was to evaluate the effect of BTX-A therapy on the physical and mental health of HFS patients.
[METHODS] Participants included 65 HFS patients and 65 matched healthy controls in the study. Cornell Medical Index (CMI) self-assessment questionnaire was used to detect the psychological health of all participants. Local injection of BTX-A was applied, and the Cohen hierarchical criteria were employed to stratify the degree of spasticity, further evaluating the efficacy of BTX-A before and two months after treatment in HFS patients. The HFS patients at two months post-treatment were re-evaluated by CMI self-assessment questionnaire, and the evaluated factors of these patients were compared with those of patients before treatment.
[RESULTS] The scores of somatization, depression, anxiety, inadaptation, sensitivity, anger, tension, M-R, and total scores in the HFS group were significantly higher than those in the control group (all P<0.05). Two months post-treatment, among 65 HFS patients who received with BTX-A treatment, 42 (64.6%) were completely relieved, 16 (24.6%) were significantly relieved, 7 (10.8%) were partially relieved, and 0 (0%) cases were invalid, and the total effective rate was 89.2%. Two months after BTX-A treatment, the scores of somatization, tension, anxiety, depression, sensitivity, M-R and total scores of patients with HFS were lower than those before treatment (all P<0.05).
[CONCLUSIONS] Patients with HFS are often accompanied by somatization, anger, inadaptation, sensitivity, anxiety, depression, and tension. BTX-A can not only alleviate the symptoms of HFS, but also improve the somatization, tension, anxiety, depression, and sensitivity.
[METHODS] Participants included 65 HFS patients and 65 matched healthy controls in the study. Cornell Medical Index (CMI) self-assessment questionnaire was used to detect the psychological health of all participants. Local injection of BTX-A was applied, and the Cohen hierarchical criteria were employed to stratify the degree of spasticity, further evaluating the efficacy of BTX-A before and two months after treatment in HFS patients. The HFS patients at two months post-treatment were re-evaluated by CMI self-assessment questionnaire, and the evaluated factors of these patients were compared with those of patients before treatment.
[RESULTS] The scores of somatization, depression, anxiety, inadaptation, sensitivity, anger, tension, M-R, and total scores in the HFS group were significantly higher than those in the control group (all P<0.05). Two months post-treatment, among 65 HFS patients who received with BTX-A treatment, 42 (64.6%) were completely relieved, 16 (24.6%) were significantly relieved, 7 (10.8%) were partially relieved, and 0 (0%) cases were invalid, and the total effective rate was 89.2%. Two months after BTX-A treatment, the scores of somatization, tension, anxiety, depression, sensitivity, M-R and total scores of patients with HFS were lower than those before treatment (all P<0.05).
[CONCLUSIONS] Patients with HFS are often accompanied by somatization, anger, inadaptation, sensitivity, anxiety, depression, and tension. BTX-A can not only alleviate the symptoms of HFS, but also improve the somatization, tension, anxiety, depression, and sensitivity.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | muscles innervated
|
scispacy | 1 | ||
| 해부 | facial nerve
|
scispacy | 1 | ||
| 약물 | botulinum toxin A
|
C0006050
botulinum toxin type A
|
scispacy | 1 | |
| 약물 | [BACKGROUND] Hemifacial
|
scispacy | 1 | ||
| 약물 | BTX-A
→ Botulinum toxin A
|
scispacy | 1 | ||
| 약물 | CMI
→ Cornell Medical Index
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] Patients
|
scispacy | 1 | ||
| 질환 | hemifacial spasm
|
C0278152
Hemifacial Spasm
|
scispacy | 1 | |
| 질환 | HFS
→ Hemifacial spasm
|
C0278152
Hemifacial Spasm
|
scispacy | 1 | |
| 질환 | spasticity
|
C0026838
Muscle Spasticity
|
scispacy | 1 | |
| 질환 | depression
|
C0011570
Mental Depression
|
scispacy | 1 | |
| 질환 | anxiety
|
C0003467
Anxiety
|
scispacy | 1 | |
| 질환 | anger
|
C0002957
Anger
|
scispacy | 1 | |
| 질환 | disease
|
scispacy | 1 | ||
| 기타 | botulinum toxin A
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | M-R
|
scispacy | 1 |
MeSH Terms
Humans; Hemifacial Spasm; Botulinum Toxins, Type A; Female; Male; Middle Aged; Neuromuscular Agents; Adult; Mental Health; Treatment Outcome; Aged; Surveys and Questionnaires; Anxiety; Depression
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.